An early landmark study by Curtin et al. identified KIT genetic aberrations in acral, mucosal, and CSD melanomas, which prompted the evaluation of several small-molecule inhibitors that were already used for GISTs, at least 80% of which harbor a KIT mutation [12]. The gene discussed is KIT; the disease is melanoma.